Senexin B
Senexin B Basic information
- Product Name:
- Senexin B
- Synonyms:
-
- 4-(2-(6-(4-methylpiperazine-1-carbonyl)naphthalen-2-yl)ethylamino)quinazoline-6-carbonitrile
- Senexin B
- Senexin B (SNX2-1-165)
- SNX2-1-165
- 6-Quinazolinecarbonitrile, 4-[[2-[6-[(4-methyl-1-piperazinyl)carbonyl]-2-naphthalenyl]ethyl]amino]-
- Senexin B, 10 mM in DMSO
- CAS:
- 1449228-40-3
- MF:
- C27H26N6O
- MW:
- 450.53
- Mol File:
- 1449228-40-3.mol
Senexin B Chemical Properties
- Boiling point:
- 724.8±60.0 °C(Predicted)
- Density
- 1.32±0.1 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- >22.6mg/mL in DMSO
- form
- Powder
- pka
- 6.74±0.10(Predicted)
- color
- White to off-white
Senexin B Usage And Synthesis
Uses
Senexin B (SNX2-1-165; BCD-115) is a potent, highly water-soluble and bioavailable CDK8/19 inhibitor, with Kds of 140 nM for CDK8 and 80 nM for CDK19.
in vivo
Pretreatment of tumor-free mice with Senexin B significantly inhibits the growth of triple-negative breast cancer (TNBC) cells inoculated into mice subsequently to Senexin B administration, indicating a general chemopreventive effect on the normal tissue "soil" . Senexin B potentiates the tumor-suppressive effect of doxorubicin on established TNBC xenografts; this effect is associated with the suppression of NFκB-mediated transcriptional induction of tumor-promoting cytokines. Senexin B inhibits invasive growth into the muscle layer in an orthotopic xenograft model of MDA-MB-468 TNBC cells. In a spleen-to-liver colon cancer metastasis model of syngeneic mouse CT26 tumors, Senexin B treatment of mice have the same effect as CDK8 knockdown in tumor cells: suppression of metastatic growth in the liver without a significant effect on primary tumor growth in the spleen[1]. Senexin B suppresses tumor growth and augmentes the effects of fulvestrant in ER-positive breast cancer xenografts[2].
IC 50
CDK19: 80 nM (Kd); CDK8: 140 nM (Kd)
References
[1] Porter D, et al. Abstract PR08: Targeting tumor microenvironment with selective small-molecule inhibitors of CDK8/19. Abstracts: AACR Special Conference on Cellular Heterogeneity in the Tumor Microenvironment; 2014 Feb 26-Mar 1; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2015;75(1 Suppl):Abstract nr PR08. doi:10.1158/1538-7445.CHTME14-PR08
[2] McDermott MS, et al. Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer. Oncotarget. 2017 Feb 21;8(8):12558-12575. DOI:10.18632/oncotarget.14894
[3] CDK8-CDK19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer. US 9321737 B2
Senexin BSupplier
- Tel
- 13186333400
- cuichengbio@163.com
- Tel
- sales@boylechem.com
- Tel
- +86-21-20908456
- sales@BioChemBest.com
- Tel
- 0371-55932928 18937192232
- 1282296214@qq.com
- Tel
- 021-52996696，15000506266 15000506266
Senexin B(1449228-40-3)Related Product Information
- Ritlecitinib
- 3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-N-(2-pyridinylmethyl)-5H-benzo[4,5]cyclohepta[1,2-b]pyridine-7-methanesulfonamide
- 2-[[(2E)-3-(2-NAPHTHALENYL)-1-OXO-2-BUTEN-1-YL]AMINO]BENZOIC ACID
- Upadacitinib
- Q-VD-OPh hydrate
- N-(2-(4'-cyanobiphenyl-4-yl)propyl)propane-2-sulfonaMide
- H3B-6527
- 2-(2-((4-bromophenyl)amino)-2-oxoethoxy)-N-(2-(methyl(phenyl)amino)-2-oxoethyl)benzamide
- (S)-4-(4-((2-(3,5-diMethylphenyl)pyrrolidin-1-yl)Methyl)phenoxy)-3-fluorobenzaMide
- BMS-986205
- Budiodarone tartrate
- COH-29